Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial

David S. Siegelb John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA

Gary J. Schillerc David Geffen School of Medicine, University of California, Los Angeles, CA, USAView further author information

Michael Sebage McGill University Health Centre, Montreal, QC, CanadaView further author information

Jesus Berdejaf Sarah Cannon Research Institute, Nashville, TN, USAView further author information

Jeffrey Matoush Colorado Blood Cancer Institute, Denver, CO, USAView further author information

Kevin Songi Vancouver General Hospital, Vancouver, BC, CanadaView further author information

Christopher S. Seetc David Geffen School of Medicine, University of California, Los Angeles, CA, USAView further author information

Mirelis Acosta-Riveraj Fundación de Investigación, San Juan, Puerto RicoView further author information

Donald Quickl Joe Arrington Cancer Research and Treatment Center, Lubbock, TX, USAView further author information

Gustavo Fonsecan Florida Cancer Specialists, St Petersburg, FL, USAView further author information

Kim Leeo Bristol Myers Squibb, Princeton, NJ, USAView further author information

Jorge Mourop Celgene International Sàrl, A Bristol-Myers Squibb Company, Boudry, SwitzerlandView further author information

Donna Reeceq Princess Margaret Cancer Centre, Toronto, ON, CanadaView further author information

Your download is now in progress and you may close this window